UroGen Pharma (URGN) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does UroGen Pharma (URGN) do?
UroGen Pharma Ltd (URGN) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Sells Jelmyto, a specialized gel chemotherapy for non-muscle invasive upper tract urothelial cancer. Develops similar localized drug delivery treatments for recurring bladder cancers. Develops hydrogel medicines that turn liquid when chilled and solidify at body temperature to treat urinary cancers. It is worth $1.56B on the market and sold $250.21M over the last year.
- Market cap
- $1.56B
- P/E ratio
- None (reported a loss)
- Annual sales
- $250.21M
- Sector
- Healthcare
- Industry
- Biotechnology
- Brief updated
- Nov 18, 2026
Brands and businesses behind URGN
- Jelmyto: Generates revenue by selling a prescription gel that delivers chemotherapy directly into the kidneys and urinary tract.
URGN’s flags, in plain English
Each flag is a number from UroGen Pharma’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.
Wide Gross Margin
Gross margin of 91.4% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Still Climbing
Sales up 56.2% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.
Stupid Cash
Can pay this year's bills 3.4 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Burning Cash
Losing money, profit margin of -26.3%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.
1 more green flag and 2 more risk notes open with the free trial. Try it free for 7 days.
Questions about URGN
How big is UroGen Pharma?
UroGen Pharma’s market cap is $1.56B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $250.21M: what customers paid the company over the last year, before any costs.
What is URGN’s P/E ratio?
URGN has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.
What could go wrong with URGN?
The business relies on a single commercial product, Jelmyto, for almost all of its product revenue. That is one risk on UroGen Pharma’s card. Its first risk flag is Burning Cash, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From UroGen Pharma’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. URGN’s filings on SEC.gov. The Margin Monkey is research, not advice.
